Drug Information

Drug (ID: DG00536) and It's Reported Resistant Information

• Name: Sotrovimab
• Synonyms: Sotrovimab
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  COVID-19 [ICD-11: 1D92]; [1]
• DrugBank ID: DB16355

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

COVID-19 [ICD-11: 1D92]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Moesin (MSN) [1]

• Resistant Disease: Corona Virus Disease 2019 [ICD-11: 1D92.0]
• Molecule Alteration: Mutations; E484K+F490S+S494P
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Hela cells; Cervix uteri; Homo sapiens (Human); CVCL_0030
• In Vitro Model: Vero E6 cells; Kideny; Homo sapiens (Human); N.A.
• In Vitro Model: BHKG43 cells; Kideny; Homo sapiens (Human); N.A.
• In Vitro Model: HEK 293T cells; Kidney; Homo sapiens (Human); CVCL_0063
• Experiment for Molecule Alteration: qRT-PCR; Deep sequencing assay
• Experiment for Drug Resistance: Immunofluorescence assay
• Mechanism Description: Monoclonal antibodies targeting the Spike protein of SARS-CoV-2 are effective against COVID-19 and might mitigate future pandemics. However, their efficacy is challenged by the emergence of antibody-resistant virus variants.

References

• Ref 1: Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis. Antiviral Res. 2024 Nov;231:106006.